| Literature DB >> 35645580 |
A Young Kim1, Jun Young Do1, Kyu Hyang Cho1, Jong Won Park1, Seok Hui Kang1.
Abstract
Purpose: As the number of patients with chronic kidney disease increases, nephrologist activities are gradually expanding. This study evaluated the safety and success of peripherally inserted central catheter (PICC) performed by nephrologists. Patients andEntities:
Keywords: catheter survival; catheter-related complication; fluoroscopy; interventional nephrology; peripheral inserted central catheter
Year: 2022 PMID: 35645580 PMCID: PMC9139328 DOI: 10.2147/IJGM.S362146
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Characteristics of the Patients and Procedures
| n (%) | |
|---|---|
| Sex (male) | 152 (53.1%) |
| Age (years) | 68.2 ± 14.0 |
| Age-adjusted Charlson comorbidity index (score) | 7.5 ± 3.0 |
| Comorbidities | |
| Non-dialysis chronic kidney disease | 28 (9.8%) |
| Dialysis | 7 (2.5%) |
| Hypertension | 115 (40.2%) |
| Diabetes mellitus | 93 (32.5%) |
| Malignancy | 202 (70.6%) |
| Use of antiplatelet or anticoagulant agents | 80 (28.0%) |
Causes of Catheter Removal
| Total = 251 | n (%) |
|---|---|
| Death | 105 (41.8%) |
| Treatment termination | 63 (25.1%) |
| Accidental removal | 35 (13.9%) |
| Infection | 29 (11.6%) |
| Occlusion | 13 (5.2%) |
| Thrombus | 6 (2.4%) |
Logistic Regression Analyses of Factors Contributing to Catheter-Related Complications
| Sex (ref: male) | 0.70 | 0.32–1.52 | 0.365 | 0.55 | 0.23–1.28 | 0.163 |
| Age (per 1-year increase) | 1.00 | 0.97–1.02 | 0.689 | 0.97 | 0.94–1.01 | 0.111 |
| DM | 3.81 | 1.73–8.38 | 0.001 | 3.30 | 1.41–7.84 | 0.006 |
| HTN | 1.57 | 0.73–3.38 | 0.246 | 1.30 | 0.55–3.08 | 0.553 |
| Cancer | 2.10 | 0.78–5.66 | 0.145 | 2.78 | 0.91–8.49 | 0.074 |
| CKD | 0.87 | 0.25–3.00 | 0.820 | 0.71 | 0.18–2.80 | 0.628 |
| Use of AP or AC agent | 3.24 | 1.50–7.03 | 0.003 | 3.51 | 1.44–8.59 | 0.01 |
| Insertion side (ref: Rt) | 0.87 | 0.40–1.90 | 0.723 | 1.11 | 0.48–2.60 | 0.816 |
| Fluoroscopy-guided insertion | 0.74 | 0.30–1.80 | 0.501 | 0.82 | 0.31–2.16 | 0.682 |
| Age-adjusted CCI | 1.12 | 0.99–1.27 | 0.08 | 1.08 | 0.93–1.26 | 0.291 |
| Sex (ref: male) | 4.12 | 1.11–15.25 | 0.034 | 4.48 | 1.19–16.91 | 0.027 |
| Age (per 1-year increase) | 1.00 | 0.96–1.04 | 0.849 | 1.01 | 0.97–1.05 | 0.694 |
| DM | 1.29 | 0.41–4.04 | 0.660 | 1.67 | 0.49–5.70 | 0.410 |
| HTN | 0.71 | 0.21–2.35 | 0.575 | 0.76 | 0.20–2.85 | 0.679 |
| Cancer | 0.65 | 0.21–2.04 | 0.460 | 0.69 | 0.17–2.70 | 0.590 |
| CKD | 0.62 | 0.08–4.93 | 0.654 | 0.68 | 0.07–6.13 | 0.727 |
| Use of AP or AC agents | 0.48 | 0.10–2.19 | 0.340 | 0.38 | 0.07–1.96 | 0.247 |
| Insertion side (ref: Rt) | 0.85 | 0.27–2.67 | 0.785 | 0.80 | 0.24–2.63 | 0.709 |
| Fluoroscopy-guided insertion | 0.53 | 0.16–1.76 | 0.298 | 0.49 | 0.14–1.78 | 0.280 |
| Age-adjusted CCI | 0.91 | 0.76–1.10 | 0.33 | 0.91 | 0.73–1.14 | 0.416 |
| Sex (ref: male) | 0.58 | 0.11–3.22 | 0.536 | 0.70 | 0.12–4.19 | 0.697 |
| Age (per 1-year increase) | 0.98 | 0.93–1.03 | 0.464 | 0.99 | 0.93–1.06 | 0.797 |
| DM | 2.08 | 0.41–10.45 | 0.376 | 2.19 | 0.36–13.33 | 0.393 |
| HTN | 1.63 | 0.32–8.21 | 0.552 | 1.42 | 0.21–9.51 | 0.716 |
| Cancer | 0.82 | 0.15–4.57 | 0.825 | 1.58 | 0.20–12.69 | 0.666 |
| CKD | 3.95 | 0.70–22.29 | 0.120 | 5.46 | 0.64–46.43 | 0.120 |
| Use of AP or AC agents | 0.53 | 0.06–4.61 | 0.566 | 0.40 | 0.04–4.07 | 0.435 |
| Insertion side (ref: Rt) | 0.53 | 0.11–2.67 | 0.442 | 0.70 | 0.12–3.89 | 0.680 |
| Fluoroscopy-guided insertion | 0.47 | 0.09–2.64 | 0.394 | 0.41 | 0.07–2.53 | 0.335 |
| Age-adjusted CCI | 0.9 | 0.69–1.17 | 0.41 | 0.84 | 0.61–1.16 | 0.296 |
Notes: Multivariate analysis was adjusted for sex, age, diabetes mellitus, hypertension, cancer, chronic kidney disease, use of AP or AC agents, insertion site, and use of fluoroscopy.
Abbreviations: OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; AP, antiplatelet; AC, anticoagulant; Rt, right; CCI, Charlson comorbidity index.
Cox Regression Analyses of Factors Contributing Catheter Survival
| Outcome: Catheter Survival | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| Sex (ref: male) | 1.24 | 0.70–2.20 | 0.459 | 1.16 | 0.65–2.09 | 0.615 |
| Age (per 1-year increase) | 0.99 | 0.98–1.02 | 0.953 | 0.99 | 0.97–1.01 | 0.331 |
| DM | 2.54 | 1.43–4.52 | 0.002 | 2.34 | 1.26–4.33 | 0.007 |
| HTN | 1.26 | 0.71–2.25 | 0.434 | 1.98 | 0.55–1.98 | 0.888 |
| Cancer | 0.93 | 0.48–1.79 | 0.818 | 1.30 | 0.61–2.74 | 0.499 |
| CKD | 1.63 | 0.69–3.86 | 0.264 | 1.37 | 0.52–3.60 | 0.530 |
| Use of AP or AC agents | 1.81 | 1.00–3.26 | 0.049 | 1.44 | 0.72–2.85 | 0.301 |
| Insertion side (ref: Rt.) | 0.79 | 0.44–1.41 | 0.423 | 1.01 | 0.55–1.86 | 0.975 |
| Fluoroscopy guided insertion | 0.49 | 0.26–0.93 | 0.029 | 0.52 | 0.27–0.10 | 0.048 |
| Age-adjusted CCI | 1.05 | 0.96–1.16 | 0.294 | 1.03 | 0.92–1.14 | 0.613 |
Notes: Multivariate analysis was adjusted for sex, age, diabetes mellitus, hypertension, cancer, chronic kidney disease, use of AP or AC agents, insertion site, and use of fluoroscopy.
Abbreviations: HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; AP, antiplatelet; AC, anticoagulant; Rt, right.